Overview
- Quarterly revenue reached $1.602 billion and adjusted EPS came in at $1.01, topping analyst expectations.
- Women's Health declined 3% to $429 million as Biosimilars grew 19% to $196 million and Established Brands rose 1% to $956 million.
- Gross margin fell to 53.5% from 58.3% on one-time manufacturing and supply-network optimization costs, while adjusted EBITDA margin improved to 32.3%.
- Guidance remained uncertain, with one account reporting a cut to $6.20–$6.25 billion and another stating the midpoint was reconfirmed at $6.23 billion.
- Pooled Phase 3 data showed Vtama cream produced early and consistent responses in children with atopic dermatitis, and shares were last up about 1.5%.